Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
207.78
-6.50 (-3.03%)
At close: Sep 18, 2026, 4:00 PM EDT
208.00
+0.22 (0.11%)
After-hours: Sep 18, 2026, 7:46 PM EDT
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $218.38M in the quarter ending June 30, 2026, with 45.54% growth. This brings the company's revenue in the last twelve months to $776.57M, up 56.87% year-over-year. In the year 2025, Axsome Therapeutics had annual revenue of $638.50M with 65.55% growth.
Revenue (ttm)
$776.57M
Revenue Growth
+56.87%
P/S Ratio
14.02
Revenue / Employee
$576,946
Employees
1,346
Market Cap
10.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 638.50M | 252.80M | 65.55% |
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Corcept Therapeutics | 830.81M |
| BridgeBio Pharma | 713.07M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 440.48M |
AXSM News
- 2 days ago - Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - GlobeNewsWire
- 3 days ago - Axsome Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 days ago - Axsome Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 8 days ago - Axsome Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 9 days ago - Axsome Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 17 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics price target raised to $316 from $306 at Mizuho - TheFly